Please enable JavaScript to continue using this application.

Compare $IKT vs $LRMR | Chartloom

Compare

$IKT vs $LRMR

Inhibikase Therapeutics Inc · Larimar Therapeutics Inc

IKT

Inhibikase Therapeutics Inc

LRMR

Larimar Therapeutics Inc

Compare $IKT vs $LRMR

Comparing Inhibikase Therapeutics Inc and Larimar Therapeutics Inc

IKTInhibikase Therapeutics Inc

LRMRLarimar Therapeutics Inc

IKTInhibikase Therapeutics Inc

Market cap

$309M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

1.0%

52W performance

18.7%

FCF yield

-13.8%

LRMRLarimar Therapeutics Inc

Market cap

$277M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-23.1%

52W performance

-44.6%

FCF yield

-56.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IKT

LRMR

Detailed metrics comparison

IKT

Inhibikase Therapeutics Inc

LRMR

Larimar Therapeutics Inc

Market Cap

IKT$309M

LRMR$277M

Enterprise Value

IKT$278M

LRMR$185M

Price

IKT$1.97

LRMR$2.67

P/E Ratio

IKTN/A

LRMRN/A

P/S Ratio

IKT872.10x

LRMR0.00x

EV/Sales

IKT774.58x

LRMR0.00x

EV/EBITDA

IKT0.00x

LRMR0.00x

P/B Ratio

IKT1.82x

LRMR2.41x

P/FCF Ratio

IKTN/A

LRMRN/A

EV/FCF

IKT-6.53x

LRMR-1.18x

PEG Ratio

IKTN/A

LRMRN/A

Forward P/E (NTM)

IKTN/A

LRMRN/A

Forward P/S (NTM)

IKTN/A

LRMRN/A

Revenue (TTM)

IKT$0

LRMR$0

Revenue Growth (YoY)

IKTN/A

LRMRN/A

Forward Rev Growth

IKT0.0%

LRMR290.4%

Gross Margin (TTM)

IKT0.0%

LRMR0.0%

Operating Margin (TTM)

IKT0.0%

LRMR0.0%

EBITDA Margin (TTM)

IKT0.0%

LRMR0.0%

Net Margin (TTM)

IKT0.0%

LRMR0.0%

FCF Margin (TTM)

IKTN/A

LRMRN/A

Net Income (TTM)

IKT$-44M

LRMR$-173M

FCF (TTM)

IKT$-43M

LRMR$-156M

EPS (TTM)

IKT-$0.25

LRMR-$1.66

ROE (TTM)

IKT-4690.0%

LRMR-13739.0%

ROA (TTM)

IKT-4348.0%

LRMR-9765.0%

ROIC (TTM)

IKT-4690.0%

LRMR-13739.0%

Cash

IKT$31M

LRMR$93M

Debt

IKT$0

LRMR$0

Net Cash/Debt

IKT$31M

LRMR$93M

Current Ratio (TTM)

IKT15.82x

LRMR4.70x

Quick Ratio (TTM)

IKT15.50x

LRMR4.58x

Debt/Equity (TTM)

IKT0.00x

LRMR0.00x

Debt/Assets (TTM)

IKT0.0%

LRMR0.0%

Interest Coverage (TTM)

IKTN/A

LRMRN/A

Net Debt/EBITDA (TTM)

IKT0.00x

LRMR0.00x

Beta

IKT0.92

LRMR0.68

52W Performance

IKT18.7%

LRMR-44.6%

YTD Performance

IKT1.0%

LRMR-23.1%

% from 52W High

IKT-24.5%

LRMR-58.4%

% from 52W Low

IKT48.1%

LRMR2.3%

Asset Turnover (TTM)

IKT0.01x

LRMR0.00x

FCF Yield (TTM)

IKT-13.8%

LRMR-56.3%

Earnings Yield (TTM)

IKT-14.3%

LRMR-62.2%

Dividend Yield (TTM)

IKTN/A

LRMRN/A

Rule of 40

IKT0.0

LRMR0.0

EV/GP/RG

IKTN/A

LRMRN/A

Ticker research

View IKT research View LRMR research

Metric	IKT Inhibikase Therapeutics Inc	LRMR Larimar Therapeutics Inc
Market & Valuation
Market Cap	$309M	$277M
Enterprise Value	$278M	$185M
Price	$1.97	$2.67
P/E Ratio	N/A	N/A
P/S Ratio	872.10x	0.00x
EV/Sales	774.58x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.82x	2.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.53x	-1.18x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	290.4%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-44M	$-173M
FCF (TTM)	$-43M	$-156M
EPS (TTM)	-$0.25	-$1.66
ROE (TTM)	-4690.0%	-13739.0%
ROA (TTM)	-4348.0%	-9765.0%
ROIC (TTM)	-4690.0%	-13739.0%
Financial Health
Cash	$31M	$93M
Debt	$0	$0
Net Cash/Debt	$31M	$93M
Current Ratio (TTM)	15.82x	4.70x
Quick Ratio (TTM)	15.50x	4.58x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.92	0.68
52W Performance	18.7%	-44.6%
YTD Performance	1.0%	-23.1%
% from 52W High	-24.5%	-58.4%
% from 52W Low	48.1%	2.3%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-13.8%	-56.3%
Earnings Yield (TTM)	-14.3%	-62.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View IKT research	View LRMR research

Valuation

P/S Ratio

LRMR

0.00x

IKT

872.10x

EV/FCF

IKT

-6.53x

LRMR

-1.18x

Growth & revenue

Forward Revenue Growth

LRMR

290.4%

IKT

0.0%

Profitability & performance

Gross Margin

IKT

0.0%

LRMR

0.0%

ROE

IKT

-4690.0%

LRMR

-13739.0%

FCF Yield %

IKT

-13.8%

LRMR

-56.3%

52-Week Performance

IKT

18.7%

LRMR

-44.6%

Detailed metrics comparison

IKT

Inhibikase Therapeutics Inc

LRMR

Larimar Therapeutics Inc

Market Cap

IKT$309M

LRMR$277M

Enterprise Value

IKT$278M

LRMR$185M

Price

IKT$1.97

LRMR$2.67

P/E Ratio

IKTN/A

LRMRN/A

P/S Ratio

IKT872.10x

LRMR0.00x

EV/Sales

IKT774.58x

LRMR0.00x

EV/EBITDA

IKT0.00x

LRMR0.00x

P/B Ratio

IKT1.82x

LRMR2.41x

P/FCF Ratio

IKTN/A

LRMRN/A

EV/FCF

IKT-6.53x

LRMR-1.18x

PEG Ratio

IKTN/A

LRMRN/A

Forward P/E (NTM)

IKTN/A

LRMRN/A

Forward P/S (NTM)

IKTN/A

LRMRN/A

Revenue (TTM)

IKT$0

LRMR$0

Revenue Growth (YoY)

IKTN/A

LRMRN/A

Forward Rev Growth

IKT0.0%

LRMR290.4%

Gross Margin (TTM)

IKT0.0%

LRMR0.0%

Operating Margin (TTM)

IKT0.0%

LRMR0.0%

EBITDA Margin (TTM)

IKT0.0%

LRMR0.0%

Net Margin (TTM)

IKT0.0%

LRMR0.0%

FCF Margin (TTM)

IKTN/A

LRMRN/A

Net Income (TTM)

IKT$-44M

LRMR$-173M

FCF (TTM)

IKT$-43M

LRMR$-156M

EPS (TTM)

IKT-$0.25

LRMR-$1.66

ROE (TTM)

IKT-4690.0%

LRMR-13739.0%

ROA (TTM)

IKT-4348.0%

LRMR-9765.0%

ROIC (TTM)

IKT-4690.0%

LRMR-13739.0%

Cash

IKT$31M

LRMR$93M

Debt

IKT$0

LRMR$0

Net Cash/Debt

IKT$31M

LRMR$93M

Current Ratio (TTM)

IKT15.82x

LRMR4.70x

Quick Ratio (TTM)

IKT15.50x

LRMR4.58x

Debt/Equity (TTM)

IKT0.00x

LRMR0.00x

Debt/Assets (TTM)

IKT0.0%

LRMR0.0%

Interest Coverage (TTM)

IKTN/A

LRMRN/A

Net Debt/EBITDA (TTM)

IKT0.00x

LRMR0.00x

Beta

IKT0.92

LRMR0.68

52W Performance

IKT18.7%

LRMR-44.6%

YTD Performance

IKT1.0%

LRMR-23.1%

% from 52W High

IKT-24.5%

LRMR-58.4%

% from 52W Low

IKT48.1%

LRMR2.3%

Asset Turnover (TTM)

IKT0.01x

LRMR0.00x

FCF Yield (TTM)

IKT-13.8%

LRMR-56.3%

Earnings Yield (TTM)

IKT-14.3%

LRMR-62.2%

Dividend Yield (TTM)

IKTN/A

LRMRN/A

Rule of 40

IKT0.0

LRMR0.0

EV/GP/RG

IKTN/A

LRMRN/A

Ticker research

View IKT research View LRMR research

Metric	IKT Inhibikase Therapeutics Inc	LRMR Larimar Therapeutics Inc
Market & Valuation
Market Cap	$309M	$277M
Enterprise Value	$278M	$185M
Price	$1.97	$2.67
P/E Ratio	N/A	N/A
P/S Ratio	872.10x	0.00x
EV/Sales	774.58x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.82x	2.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.53x	-1.18x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	290.4%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-44M	$-173M
FCF (TTM)	$-43M	$-156M
EPS (TTM)	-$0.25	-$1.66
ROE (TTM)	-4690.0%	-13739.0%
ROA (TTM)	-4348.0%	-9765.0%
ROIC (TTM)	-4690.0%	-13739.0%
Financial Health
Cash	$31M	$93M
Debt	$0	$0
Net Cash/Debt	$31M	$93M
Current Ratio (TTM)	15.82x	4.70x
Quick Ratio (TTM)	15.50x	4.58x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.92	0.68
52W Performance	18.7%	-44.6%
YTD Performance	1.0%	-23.1%
% from 52W High	-24.5%	-58.4%
% from 52W Low	48.1%	2.3%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-13.8%	-56.3%
Earnings Yield (TTM)	-14.3%	-62.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View IKT research	View LRMR research